SCHEMBL5513752

SCHEMBL5513752

NC[C@H]1CC[C@@H](OCCc2ccccc2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.41
SLC6A4 P31645 1/20 0.41
SLC6A3 Q01959 1/20 0.41
DPP4 P27487 1/20 0.40
TAAR1 Q96RJ0 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
CYP2A6 P11509 1/20 0.39
HTR2A P28223 1/20 0.39
LOXL2 Q9Y4K0 1/20 0.39
F2 P00734 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
IDO1 P14902 1/20 0.38
KDM1A O60341 1/20 0.38
MAOB P27338 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
HSD17B3 P37058 1/20 0.37
MC4R P32245 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5513756 1.00 SLC6A2 (0.41) SLC6A2SLC6A4SLC6A3DPP4TAAR1
Hydrochloric Acid SCHEMBL5514715 0.98 SLC6A2 (0.41) SLC6A2SLC6A4SLC6A3DPP4TAAR1
Hydrochloric Acid SCHEMBL5514718 0.98 SLC6A2 (0.41) SLC6A2SLC6A4SLC6A3DPP4TAAR1
SCHEMBL5007137 0.85 LTA4H (0.43) SMN1; SMN2HTR2ANPC1RAB9AHSD17B3
SCHEMBL5007136 0.85 LTA4H (0.43) SMN1; SMN2HTR2ANPC1RAB9AHSD17B3
SCHEMBL5518823 0.83 DPP4 (0.56) SLC6A2SLC6A4SLC6A3DPP4HTR2A
SCHEMBL5518818 0.83 DPP4 (0.56) SLC6A2SLC6A4SLC6A3DPP4HTR2A
SCHEMBL5009550 0.83 CA1 (0.41) DPP4TAAR1SMN1; SMN2CYP2A6HTR2A
SCHEMBL5009548 0.83 CA1 (0.41) DPP4TAAR1SMN1; SMN2CYP2A6HTR2A
SCHEMBL5519368 0.81 OPRM1 (0.42) SLC6A2SLC6A4SLC6A3HSD17B3MC4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167452-A1 Therapeutic amide derivatives PFIZER, INC. 2007-07-19 US disclosed
US-20070167452-A1 Therapeutic amide derivatives PFIZER, INC. 2007-07-19 US disclosed
US-20070037829-A1 e.g. trans-(4-Phenethyloxy-cyclohexyl)-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine; neurodegenerative disorders, analgesic, antidepressant, anxiolytic agent; Parkinson's disease, Alzheimer's disease, epilepsy, ischemic brain injury, stroke; with other active ingredients MERCK & CO., INC. (US) 2007-02-15 US disclosed
EP-1656379-B1 4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS MERCK & CO INC (US) 2007-01-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167452-A1 Therapeutic amide derivatives GRIN1, GRIN2B, GRIN3A SLC6A2 577/4885SLC6A4 834/4885SLC6A3 638/4885
US-20070037829-A1 e.g. trans-(4-Phenethyloxy-cyclohexyl)-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine; neurodegenerative disorders, analgesic, antidepressant, anxiolytic agent; Parkinson's disease, Alzheimer's disease, epilepsy, ischemic brain injury, stroke; with other active ingredients GRIN2B, GRIN3A, GRIN2A SLC6A2 869/4885SLC6A4 343/4885SLC6A3 507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.